However, the rapidly changing viral variants with mutations in spike protein that resulted in reduced binding affinity of monoclonal antibody is a significant challenge to the therapeutic lifespan of the COVID-19 anti-spike monoclonal antibodies16. The gene discussed is CHMP5; the disease is COVID-19.